Biogen (BIIB) Stock Price Target 2026

The average analyst price target for Biogen is $248.26, 3.6% below the current price. Of 25 analysts, 19 rate it Buy and 6 Hold. Targets range from $157 to $310. The latest change came on Nov 9, 2026, when Piper Sandler raised its price target on Biogen from $245 to $305 and kept an Overweight rating.

The Average Analyst Price Target for Biogen is $248.26.

Price Target Range — 7 Quarters

Analyst Consensus — 25 Analysts

19Buy

6Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$248.26Upside to Avg. PT-3.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Biogen Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 9, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$245→$305
Nov 2, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$280→$300
Nov 2, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$251→$270
Oct 29, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$248→$272
Oct 29, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$280
Oct 29, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$256→$272
Oct 29, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$231→$238
Oct 29, 2026	UBS	Michael Yee	PT Raise	Buy	$270→$300
Oct 29, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$250→$260
Oct 29, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$212→$225
Oct 29, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$235→$260
Oct 29, 2026	Baird	Brian Skorney	PT Raise	Outperform	$250→$290
Oct 29, 2026	Needham	Ami Fadia	PT Raise	Buy	$256→$290
Oct 28, 2026	Barclays	Emily Field	PT Raise	Equal-Weight	$200→$230
Oct 22, 2026	B of A Securities	Jason Zemansky	PT Raise	Neutral	$219→$244
Oct 21, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$225→$250
Oct 20, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$250→$310
Oct 12, 2026	JP Morgan	Chris Schott	Upgrade	Neutral→Overweight	$210→$300
Oct 9, 2026	UBS	Michael Yee	PT Raise	Buy	$240→$270
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$260→$256